Latest news

Vulgaroo remporte le 9e Challenge qualité de vie du patient avec un prix de 25’000 francs suisse

CARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae Infections

Debiopharm to Showcase Research Results of Their First-In-Class Anti-Staphylococcal Program at IDWeek 2024 in Los Angeles

Debiopharm Recognizes Groundbreaking Japanese Cancer Research During the 83rd Annual Meeting of the Japanese Cancer Association

Debiopharm and WhiteLab Genomics announce a collaboration to advance drug target and design in Oncology

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-Based Radiopharmaceutical Programs Targeting Solid Tumors

Debiopharm pose la première pierre de son nouveau bâtiment pouvant accueillir jusqu’à 300 collaborateurs tout en sortant des énergies fossilles…

First Patients Dosed in Debiopharm’s Phase III Trial (LIBELULA) Investigating Debio 4326, A 12-Month Triptorelin Formulation for Children with Central…

Debiopharm Underlines Commitment to Eradicating Antimicrobial Resistance by Sponsoring the 8th Annual World AMR Conference